Eisai’s Alzheimer’s Drug Clears Advisory Panel, Now in Line for Japan Approval

Eisai’s lecanemab gained the blessing of a key health ministry panel on August 21, setting the stage for its regulatory approval soon as Japan’s first Alzheimer’s disease (AD)-modifying therapy. All eyes will now shift to its pricing and reimbursement. Lecanemab...read more